glp3.wiki

What Is Foundayo (Orforglipron)? Lilly's Oral GLP-1 Pill

Regulatory status

Editorially reviewed · Last updated September 8, 2026 · How we review

Foundayo is the brand name; orforglipron is the active ingredient’s generic name. It is an FDA-approved oral GLP-1 receptor agonist developed by Eli Lilly. The FDA approved Foundayo on April 1, 2026, making it the second oral GLP-1 pill approved for obesity (after the Wegovy pill in December 2025) and the first non-peptide oral GLP-1 agonist ever approved. Orforglipron is a non-peptide small molecule taken once daily, with no food or water timing restrictions. Oral semaglutide is a peptide tablet with different administration requirements.
In the Phase 3 ATTAIN-1 trial, the highest studied dose produced 12.4% average weight loss at 72 weeks in the efficacy analysis. The FDA label reports 11.1% in its analysis including treatment discontinuation, versus 2.1% on placebo. In a head-to-head diabetes trial (ACHIEVE-3), it outperformed oral semaglutide on both HbA1c reduction and weight loss. The FDA fast-tracked Foundayo under its Commissioner's National Priority Voucher program — the approval took just 50 days after filing, the fastest for a new molecular entity since 2002.
Foundayo is available at pharmacies and through LillyDirect with free home delivery, starting at $149/month for self-pay patients. It is part of Eli Lilly's broader weight loss portfolio alongside tirzepatide (Mounjaro/Zepbound) and retatrutide.

How does the oral non-peptide work?

A Non-Peptide GLP-1 Agonist

Semaglutide, tirzepatide and liraglutide are peptides. Digestion makes oral peptide delivery difficult, but semaglutide tablets use an absorption-enhancing formulation. Foundayo is different because its active ingredient is a non-peptide small molecule.

Orforglipron solves this by being a non-peptide small molecule. It is chemically synthesized (not biologically derived) and is stable in the gastrointestinal tract. This means:
  • No injection needed — taken as a once-daily oral pill
  • No fasting required — unlike oral semaglutide (Rybelsus), which requires 30 minutes of fasting with only a sip of water
  • No food or water restrictions — can be taken at any time of day with or without meals

Biased Agonism

According to Lilly Medical, orforglipron binds to the same GLP-1 receptor as native GLP-1 but exhibits biased agonism — it favors G-protein signaling (specifically cAMP accumulation, which drives the therapeutic effects) over beta-arrestin recruitment (which leads to receptor downregulation).

In practical terms: orforglipron activates the receptor's beneficial pathways (appetite suppression, insulin secretion, slowed gastric emptying) while potentially causing less receptor desensitization over time. This is a partial agonist — it does not fully activate the receptor to the same extent as injectable GLP-1 peptides.

What It Does in the Body

Like all GLP-1 receptor agonists, orforglipron:

  • Reduces appetite by acting on GLP-1 receptors in the hypothalamus
  • Stimulates insulin secretion in response to food (glucose-dependent)
  • Suppresses glucagon after meals, preventing excess liver glucose output
  • Slows gastric emptying, prolonging fullness after eating

The same receptor, the same downstream effects — just delivered in a pill instead of a needle.

What did the trials show?

ATTAIN-1 (Phase 3 — Obesity Without Diabetes)

ATTAIN-1 enrolled 3,127 adults without diabetes and followed them for 72 weeks. The FDA label reports the following results using equivalent marketed Foundayo strengths and an analysis that includes treatment discontinuation:

Swipe sideways to see every column.

Foundayo-equivalent daily doseAverage weight lossLost at least 10%Lost at least 15%
5.5 mg7.4%32.5%14.3%
9 mg8.3%39.8%20.1%
17.2 mg11.1%54.5%35.9%
Placebo2.1%13.0%6.0%
The earlier trial report used investigational formulation strengths of 6, 12 and 36 mg. Its highest-dose efficacy estimand reported 12.4% loss, assuming continued treatment. Different formulations and analyses explain why those numbers differ from the approved label; trial milligrams are not a self-conversion guide.

Among participants with prediabetes, the report describes a return to near-normal glucose levels. That is not the same endpoint as proving prevention of type 2 diabetes.

ACHIEVE-3 (Phase 3 — Head-to-Head vs Oral Semaglutide in T2D)

The ACHIEVE-3 trial, published in The Lancet in February 2026, was the first head-to-head trial comparing two oral GLP-1 therapies. The 52-week, open-label trial enrolled 1,698 adults with type 2 diabetes on metformin. The table below uses the efficacy estimand and investigational formulation doses, not the marketed Foundayo tablet strengths:

Swipe sideways to see every column.

Oral Semaglutide 7 mgOral Semaglutide 14 mgOrforglipron 12 mgOrforglipron 36 mg
HbA1c reduction-1.1%-1.4%-1.9%-2.2%
Weight loss—-5.3%—-9.2%
HbA1c under 7%—66.1%—85.4%
Orforglipron 36 mg produced 73.6% greater relative weight loss than oral semaglutide 14 mg. It also outperformed on every primary and key secondary endpoint.
Important caveat: the oral semaglutide doses used (7 mg and 14 mg) are the diabetes-indication doses. Novo Nordisk's obesity-indication oral semaglutide (the Wegovy pill, approved December 2025) goes up to 25 mg, which was not tested in this trial. The result cannot be extended to that higher-dose product.

Phase 2 (Obesity)

The earlier Phase 2 trial randomized 272 adults without diabetes. At 36 weeks, average weight loss ranged from 9.4% to 14.7% across the investigational 12–45 mg dose groups, versus 2.3% on placebo. These research formulations are not the approved tablet strengths.

What is the daily titration schedule?

The FDA label starts Foundayo at 0.8 mg once daily for at least 30 days, then 2.5 mg for at least 30 days, then 5.5 mg. A prescriber may increase to 9 mg, 14.5 mg and 17.2 mg, allowing at least 30 days at each dose, according to response and tolerability.
17.2 mg is the maximum dose, not a required target for everyone. Drug interactions can change the permitted dose. Swallow the tablet whole, take no more than one tablet daily, and follow the prescriber’s instructions.

What side effects showed up in trials?

The side effect profile is consistent with the GLP-1 drug class, though GI side effects may be somewhat more pronounced than with oral semaglutide.

From the Pooled Weight-Management Trials

The current label pools two 72-week weight-management trials, with and without type 2 diabetes. At the 17.2 mg equivalent dose, nausea occurred in 35%, diarrhea in 25%, vomiting in 24% and constipation in 24%, versus 10%, 11%, 4% and 9% with placebo. These pooled figures are not ATTAIN-1-only rates.

Adverse reactions led to discontinuation in 10% at 17.2 mg versus 3% on placebo; GI reactions led to discontinuation in 6% versus 0.7%. Rates from separate drug trials cannot establish relative severity.

The label also includes a boxed warning about thyroid C-cell tumors and contraindications for personal or family history of medullary thyroid carcinoma or MEN2. Severe stomach symptoms, dehydration, pancreatitis, gallbladder disease and medicine interactions need clinical attention. It is not recommended with another GLP-1 agonist.

How does the pill compare to other drugs?

Foundayo is a daily non-peptide GLP-1 tablet. The Wegovy pill contains the peptide semaglutide and has fasting and water instructions. Zepbound is a weekly tirzepatide injection targeting GLP-1 and GIP; retatrutide is an investigational triple agonist.

ACHIEVE-3 provides a direct comparison with diabetes-dose oral semaglutide. It does not compare Foundayo with the Wegovy obesity pill, Zepbound or retatrutide. Separate headline percentages cannot establish those comparisons.

How does it compare to retatrutide?

Foundayo is FDA approved for adult weight management. Retatrutide remains investigational and is administered by injection in trials.
Route and approval status are clear differences. The evidence summarized here does not establish that one should be a first-line treatment and the other reserved for severe obesity or plateaus. See our retatrutide vs orforglipron comparison.

When was it approved, and what does it cost?

The FDA approved Foundayo (orforglipron) on April 1, 2026, for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. It was approved under the FDA's Commissioner's National Priority Voucher program — the fastest new molecular entity approval since 2002, issued just 50 days after filing.

Foundayo became available at pharmacies and through LillyDirect with free home delivery starting April 6, 2026.

What does it cost?

As checked on September 8, 2026, Lilly’s self-pay terms list these prices per 30-day supply for eligible patients:
DoseSelf-pay offer
0.8 mg$149
2.5 mg$149 through December 31, 2026; regular $199
5.5 mg$199 through December 31, 2026; regular $299
9 mg$299
14.5 or 17.2 mg$299 with the refill offer; regular $349

The $299 offer for 14.5 and 17.2 mg requires subsequent refill purchases within 45 days. Eligible commercially insured patients with coverage may pay as little as $25, subject to savings limits and program terms.

The Medicare GLP-1 Bridge began July 1, 2026 and offers a $50 monthly copay to beneficiaries who meet its eligibility criteria. This is not an average Part D price or universal coverage. Confirm the current terms and your eligibility before relying on a price.

Frequently Asked Questions

What is Foundayo (orforglipron)?

Foundayo is an FDA-approved oral GLP-1 weight loss pill made by Eli Lilly. Its active ingredient is orforglipron, a non-peptide small molecule that can be taken once daily without injections, fasting, or food restrictions. It was approved on April 1, 2026.

How much weight can you lose on Foundayo?

The FDA label reports average loss of 11.1% with the highest equivalent dose at 72 weeks in adults without diabetes, versus 2.1% on placebo. The earlier efficacy analysis reported 12.4%, assuming continued treatment. Individual results vary.

Is Foundayo a pill or injection?

Foundayo is a once-daily oral pill. It is the first non-peptide GLP-1 receptor agonist — a small molecule that survives stomach acid and digestive enzymes, so it can be taken by mouth at any time of day with no food or water restrictions.

How much does Foundayo cost?

Eligible self-pay patients can start at $149 per 30-day supply. Higher-dose prices and temporary offers vary; the 14.5 and 17.2 mg $299 offer has a 45-day refill condition, with regular pricing of $349. Commercial savings and Medicare Bridge eligibility are separate.

Do you have to take Foundayo on an empty stomach?

No. Unlike the Wegovy pill (oral semaglutide), which requires 30 minutes of fasting with only a sip of water, Foundayo can be taken at any time of day with or without food and with no water restrictions. This is one of its key advantages over other oral GLP-1 drugs.

What is the difference between Foundayo and Zepbound?

Foundayo is a daily oral GLP-1 agonist; Zepbound is a weekly injectable GLP-1/GIP agonist. Both are approved medicines from Lilly, but they are different drugs. The trials summarized here do not directly compare them.

What are Foundayo's side effects?

In the pooled weight-management trials, nausea, diarrhea, vomiting and constipation were common. At the highest equivalent dose, rates were 35%, 25%, 24% and 24%, respectively. The label also has important warnings and contraindications; a pill is not free of GLP-1-related risks.

How does Foundayo compare to the Wegovy pill?

Foundayo has no food or water timing restrictions; Wegovy’s pill has specific fasting and water instructions. ACHIEVE-3 tested diabetes-dose oral semaglutide, not the Wegovy obesity pill, so it does not establish comparative weight loss between these products.

Is Foundayo better than Ozempic?

ACHIEVE-3 compared orforglipron with oral semaglutide at diabetes doses, not injected Ozempic. It cannot establish that Foundayo is better than Ozempic or predict the result of a different dose comparison.

Sources

  1. Wharton S, et al. "Orforglipron in adults with obesity." New England Journal of Medicine. 2025. Lilly Press Release
  2. Rosenstock J, et al. "Orforglipron vs oral semaglutide in type 2 diabetes (ACHIEVE-3)." The Lancet. 2026. Lilly Press Release
  3. Sloop KW, et al. "The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron." PubMed
  4. Kansakar U, et al. "Orforglipron: A Comprehensive Review." Int J Mol Sci. 2026;27(3):1409. PMC
  5. Eli Lilly. "Mechanism of action of orforglipron." Lilly Medical
  6. Park A. "FDA Approves Eli Lilly's Obesity Pill, Foundayo." Time. April 2, 2026. Time
  7. Lupkin S. "Eli Lilly obesity pill Foundayo gets the FDA green light." NPR. April 1, 2026. NPR
  8. Drugs.com. "How much does Foundayo cost?" April 2026. Drugs.com
How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Foundayo (orforglipron) is FDA approved for adult weight management. Retatrutide remains investigational.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all drugs topics →